Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Chengdu Kanghong's KH815 enters human testing this month.
AACR approaches, along with ASCO abstract titles.
A biliary tract cancer trial hits on response rate, but survival data will be key.
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
